A Study of Ipatasertib (GDC-0068) in Combination With Paclitaxel as Neoadjuvant Treatment for Participants With Early Stage Triple Negative Breast Cancer
Public ClinicalTrials.gov record NCT02301988. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase II Randomized, Double-Blind, Study of Ipatasertib (GDC-0068), an Inhibitor to AKT, in Combination With Paclitaxel as Neoadjuvant Treatment for Patients With Early Stage Triple Negative Breast Cancer
Study identification
- NCT ID
- NCT02301988
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Genentech, Inc.
- Industry
- Enrollment
- 151 participants
Conditions and interventions
Conditions
Interventions
- Ipatasertib Drug
- Paclitaxel Drug
- Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 16, 2015
- Primary completion
- Aug 1, 2017
- Completion
- Aug 1, 2017
- Last update posted
- Oct 16, 2018
2015 – 2017
United States locations
- U.S. sites
- 16
- U.S. states
- 10
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Arizona Oncology Associates, PC-CASA | Tucson | Arizona | 85704 | — |
| Sansum Medical Clinic, Inc. | Santa Barbara | California | 93105 | — |
| Rocky Mountain Cancer Center - Lakewood (West) | Lakewood | Colorado | 80228 | — |
| Massachusetts General Hospital | Boston | Massachusetts | 02114 | — |
| Mass General/North Shore Cancer | Danvers | Massachusetts | 01923 | — |
| Nebraska Cancer Specialists; Oncology Hematology West, PC | Omaha | Nebraska | 68130 | — |
| Carolinas Healthcare System | Charlotte | North Carolina | 28208 | — |
| Northwest Cancer Specialists - Portland (NE Hoyt St) | Portland | Oregon | 97213 | — |
| Roper Bon Secours St. Francis Cancer Center | Charleston | South Carolina | 29414 | — |
| Texas Oncology | Austin | Texas | 78705 | — |
| Texas Oncology Cancer Center | Austin | Texas | 78731 | — |
| Texas Oncology - Baylor Charles A. Sammons Cancer Center | Dallas | Texas | 75246 | — |
| Texas Oncology - Houston (Gessner) | Houston | Texas | 77024 | — |
| Texas Oncology-Tyler | Irving | Texas | 75063 | — |
| South Texas Cancer Center - McAllen | McAllen | Texas | 78503 | — |
| Northwest Medical Specialties, PLLC | Tacoma | Washington | 98405 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 26 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02301988, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 16, 2018 · Synced Jun 25, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02301988 live on ClinicalTrials.gov.